drugset / Trial / NCT00402480

Hydroxyurea to Prevent Stroke in Children With Sickle Cell Anemia and Elevated TCD Flow Velocity

NCT00402480

Phase 2 Completed 50 enrolled Duke University
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess prospectively the efficacy of hydroxyurea therapy in the setting of cerebrovascular disease, manifest as conditional or abnormal transcranial doppler ultrasonography (TCD) flow velocities, in children with sickle cell anemia (SCA). TCD is used to measure flow velocity in intracranial arteries as a marker of increased stroke risk in children with SCA. The primary objective of this protocol is to determine whether hydroxyurea reduces elevated TCD velocity.

Timeline

Start
2003-04
Primary completion
Completion
2006-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxyurea Other / unclassified

Indications